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Abstract
Purpose of Review To provide an overview of recent studies of coronary computed tomography angiography (CCTA) and how it
has helped to improve clinical outcomes for patients presenting with chest pain.
Recent Findings Randomised controlled trials have uniformly demonstrated that the use of CCTA is associated with improve-
ments in patient diagnosis, management and treatments as well as the avoidance of unnecessary invasive coronary angiography.
These changes have been associated with consistent reductions in long-term rates of fatal or non-fatal myocardial infarction.
Summary Major beneficial effects in clinical management and patient outcomes are seen with the use of coronary computed
tomography angiography. CCTA might be considered to be the first test of choice for the investigation of coronary heart disease.
Keywords Computed tomography coronary angiography . Coronary artery disease . Exercise electrocardiography . Stress
echocardiography .Myocardial perfusion imaging . Cardiacmagnetic resonance imaging
Introduction
Cardiovascular disease and coronary artery disease are the
primary causes of morbidity and mortality in developed coun-
tries [1–3]. In the past, obstructive coronary disease was large-
ly studied with indirect diagnostic tests that assess cardiac
ischaemia. These tests have developed over time from the
exercise electrocardiogram to myocardial perfusion imaging
with single-photon emission computed tomography, stress
echocardiography, positron emission tomography, and mag-
netic resonance imaging. They have provided important prog-
nostic information and have been the focus of the most recent
international guidelines for the investigation of stable chest
pain [4, 5]. Although they can demonstrate inducible ischae-
mia suggestive of obstructive coronary disease, they are
unable to detect non-obstructive coronary artery disease, and
the use of these tests has not led to improved clinical outcomes
within the setting of randomised controlled trials [4–9]. In
contrast, coronary computed tomography angiography
(CCTA) has the ability to identify patients with obstructive
and non-obstructive coronary heart disease with high sensitiv-
ity and specificity [10, 11]. In addition in comparison to func-
tion imaging, CCTA use has been associated with reduced
non-fatal myocardial infarctions and coronary heart disease
death [12, 13].
Evolution of Coronary Computed
Tomography Angiography
Coronary computed tomography angiography is being in-
creasingly utilised in clinical practice for evaluating coronary
anatomy for obstructive disease and plaque. Computed to-
mography was first introduced by Sir Godfrey Hounsfield in
the 1970 and the first commercial scanner was available at
1972. In the early 1980s, an important advance helps to dem-
onstrate the potential for CT technology to image the moving
heart. This was the introduction of the electron beam comput-
ed tomography (EBCT) by Douglas Boyd. This technology
decreased scan times and improved temporal resolution. For
the first time, it was possible to view cardiac contractions and
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to visualise small structures such as calcium deposits within
the walls of the coronary artery. A limitation of EBCT is the
spatial resolution due to the slice width of 1.5 mm. An addi-
tional major advance in computed tomography imaging came
in the early 1990s with the introduction of multidector com-
puted tomography (MDCT) that could rotate 360°. With these
advances, spatial resolution improved due to multidetection
technology and temporal resolution compromise was reduced
since the X-ray beam was able to rotate continuously around
the patient as they moved through the scanner [14]. Early
multi-detector row computed tomography scanners intro-
duced in 1998 had four detector rings and were capable of
half a second gantry rotations. Today’s multidetector comput-
ed tomography scanners have up to 320-detector rings, gantry
rotation times as low as 270 msec, and in some cases, two x-
ray sources, allowing submillimeter resolution to be acquired
over very large volumes in a fraction of a second. Faster vol-
ume coverage also allowed a sizable reduction in contrast
media usage [15].
According to the current European Society of Cardiology
guidelines and American College of Cardiology and
American Heart Association appropriate-use criteria, CCTA
is a level IIa recommendation as an alternative to a stress test
for ruling out stable coronary artery disease in patients with
low to intermediate pre-test probability [4, 5]. In contrast, the
2016 update to the National Institute for health and Care
Excellence (NICE) chest pain guideline (CG95) recommends
CCTA as the first-line test for the evaluation of coronary artery
disease in stable chest pain pathways [16]. This guideline is
based predominantly on the diagnostic precision and cost ef-
fectiveness of this strategy compared to invasive coronary
angiography.
Evaluating Patients with Chest
Pain–Functional Assessment
Patients attending the emergency department and outpatient
department with chest pain account for almost half of all ad-
missions [17]. The initial evaluation includes history taking,
physical examination, ECG and clinical biochemistry and is
aiming to identify high-risk patients and those with an acute
myocardial infarction. If an acute coronary syndrome is ex-
cluded, then questions remain if the pain is cardiac or not, and
whether the patient has coronary artery disease. These ques-
tions have been troubling physicians for decades. The present-
ing complaint is frequently atypical in nature, and clinicians
are faced with the dual task of avoiding unnecessary investi-
gations whilst also ensuring the safe and efficient identifica-
tion of those individuals with underlying coronary heart dis-
ease. To answer these questions, several functional and ana-
tomical tests have been developed throughout the years.
Exercise treadmill test has been the cornerstone method for
evaluating patients with stable chest pain for several decades.
Depending on the results, the patient would often receive ei-
ther medical therapy or be referred for invasive angiography.
Although this test is cheap and cost-effective, its sensitivity
and specificity remain low (61% and 70%, respectively), and
it is even lower in women [18, 19] and lower than other func-
tional imaging modalities [20] leading to unnecessary inva-
sive angiograms or to undertreatment of patients with
unrecognised and undiagnosed coronary artery disease
(CAPP McKavanagh et al.).
The sensitivity and specificity of functional imaging tests
have been reviewed extensively in multiple systematic reviews
and meta-analyses (Table 1). Exercise and pharmacological
stress echocardiography [21, 22], exercise and pharmacological
stress nuclear myocardial perfusion imaging (MPI) [21, 23–25]
and pharmacological stress cardiovascular magnetic resonance
(CMR) [26, 27] demonstrate an association between abnormal
test results and the detection of obstructive coronary artery dis-
ease on invasive angiography, as well as an increased risk of
adverse cardiovascular events. Randomised controlled trials of
functional stress tests that have, however, failed to demonstrate
better downstream clinical outcomes in comparison to CCTA
(PROMISE, CAPP).
Evaluating Patients with Chest
Pain–Anatomical Assessment
With the 64-slice detector computed tomography becoming the
minimum standard, the improved temporal and spatial resolution
allowed for a high degree of image quality assessment of coro-
nary arteries with CCTA. The extent and severity of angiograph-
ic coronary artery disease are amongst the most important prog-
nostic factors and remain vital determinants for revascularisation
decision making [28]. Several meta-analyses and clinical trials
have reported the diagnostic accuracy of CCTA with 64-slice
computed tomography, with sensitivity ranging from 93 to
97% and specificity varying from 90 to 96% [8, 11, 29–33] for
Table 1 Sensitivity and specificity of different functional assessments
for obstructive coronary artery disease
Functional test Sensitivity Specificity
Exercise electrocardiography 61% 70%
Exercise stress echocardiography 70–85% 77–89%
Pharmacological stress echocardiography 85–90% 75–90%
Exercise stress SPECT 82–88% 70–88%
Pharmacological stress SPECT 88–91% 75–90%
Dobutamine cardiac magnetic resonance 83% 86%
Adenosine cardiac magnetic resonance 91% 81%
SPECT single-photon emission computed tomography
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identifying obstructive coronary artery disease. Its very high
negative predictive value can reassure clinicians and of course
give patients peace of mind (CAPP and Scot Heart)—this is
extending the CAPP findings that CT reduced ER visits in com-
parison to treadmill testing. Williams et al. [32] showed that
following a strategy of CCTAversus usual care, subsequent
clinically requested invasive coronary angiography was less
likely to demonstrate normal coronary arteries in the CCTA
arm in comparison to usual care (20 vs. 56, respectively; HR:
0.39 [95% CI: 0.23 to 0.68]; p < 0.001) and more likely to
showobstructivecoronaryarterydisease(283vs.230,respec-
tively; HR: 1.29 [95% CI: 1.08 to 1.55]; p = 0.005) in the
Scottish COmputed Tomography of the HEART (SCOT-
HEART) trial (Figs. 1 and 2). In this study, the authors dem-
onstrated that the addition ofCCTA to routine clinical assess-
ment of patients with suspected angina pectoris secondary to
coronaryheartdisease leads toanearly3-fold reduction in the
rates of normal invasive coronary angiography.
In addition to precisely detecting obstructive coronary ar-
tery disease [34], CCTA provides prognostic information re-
lated to the presence and extent of non-obstructive plaque
[35]. Since the incidence of nonobstructive plaque is more
likely to be recognised by CCTA, it is associated with a higher
use of downstream preventive therapies and better risk factor
control, therefore leading to improved outcomes [36–38].
CCTA also reliably illustrates the morphology and composi-
tion of coronary atherosclerosis, including high-risk plaque
features, such as positive remodelling and low attenuation
plaque disease (Fig. 3).
Asymptomatic Individuals
The FACTOR-64 trial [39] has been the only CCTA trial
in primary prevention, and it specifically recruited 900
patients with type 1 or 2 diabetes mellitus only.
Participants found to have coronary heart disease on
Fig. 1 Patient with typical anginal symptoms listed for invasive
angiogram following baseline clinical assessment in the SCOT-HEART
trial. Normal coronary arteries on coronary computed tomography
angiography. Management changes after coronary computed
tomography angiography and was treated conservatively. Patients
assigned to the coronary computed tomography angiography arm had a
reduced likelihood of demonstrating normal coronary arteries in the
invasive angiogram (P < 0.001) hazards ratio 0.392 (95% CI, 0.227–
0.676) (Reprinted from Williams et al. JACC 2016;67:1759–1768
under terms of CC BY 4.0)
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computed tomography coronary angiography were
targeted for more intensive risk factor modification al-
though 75% of trial participants were already on a statin
at baseline. Compared to standard of care, those assigned
to CCTA had an LDL-cholesterol concentration that was
0.06 mmol/L lower (p = 0.02), but there was no differ-
ence in blood pressure or haemoglobin A1c concentra-
tions. In the intention-to-treat analysis, the primary end-
point occurred in 6.2% of the CCTA group compared to
7.6% in the control group (hazard ratio, 0.80 [95% con-
fidence interval, 0.49–1.32]; p = 0.38). In the as-treated
analysis, the respective event rates were 5.6% vs 7.9%
(hazard ratio, 0.69 [95% confidence interval, 0.41–1.16];
p = 0.16). The failure to demonstrate a benefit is there-
fore likely to represent the inability to deliver a major
difference in treatment and management consequent on
the application of the imaging test and a lack of power
due to the small sample size and lower than anticipated
event rate.
Patients with Stable Chest Pain
Several studies have demonstrated improved outcomes when
CCTA is added to standard care in patients with stable chest
pain (Table 2). Recently, our group reported the 5-year out-
comes of the SCOT-HEART trial where we identified a 41%
reduction in the composite endpoint of coronary heart disease
death or non-fatal myocardial infarction amongst participants
randomised to the CCTA in addition to standard of care [12].
This observed lower rate of the primary clinical end point was
driven mainly by a lower rate of non-fatal myocardial
infarction.
Although in the first 12 months, there was an increase in
the invasive angiograms and coronary revascularisation per-
formed in the CCTA group, there was no difference between
the two groups in terms of invasive angiography or coronary
revascularisation by 5 years of follow-up [12]. This is consis-
tent with better and earlier identification of disease that led to
more appropriate invasive angiography and coronary
Fig. 2 Patient in the SCOT-HEART trial who presented with atypical
non-anginal chest pain and was managed conservatively at the baseline
clinic assessment. Obstructive coronary artery disease identified on
coronary computed tomography angiography. Patients assigned to the
coronary computed tomography angiography arm had an increased
likelihood of identifying obstructive coronary artery disease in invasive
angiogram (P = 0.005), hazards ratio 1.293 (95% CI, 1.081–1.548)
(Reprinted from Williams et al. JACC 2016;67:1759–1768 under terms
of CC BY 4.0)
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revascularisation in the first year. Indeed, other trials with
short-term follow-up have also shown higher rates of invasive
coronary angiography and coronary revascularisation after
coronary computed tomography angiography than after func-
tional testing [40]. However, beyond 1 year in the SCOT-
HEART trial, the prior increase in revascularisation appeared
to pay dividends because the rates of invasive angiography
and coronary revascularisation became lower than the stan-
dard of care group suggesting progression of untreated
unrecognised disease in those who had not undergone a
CCTA. Whilst it is plausible that early revascularisation
played a role in the observed long-term difference in events,
the benefits are likely to be mostly attributable to changes in
medical management.
The benefits of preventative medical therapy are well de-
scribed in major randomised controlled trials. Nevertheless, it
should be remembered that many trials (particularly primary
prevention trials) treated a general and broad population of
patients at risk of cardiovascular disease. Most of these trial
participants did not have cardiovascular disease and they had
no chance of benefiting from the intervention. In SCOT-
HEART, we identified a population with the disease before
treatment initiation, which potentially led to greater proportion-
ate benefits. Similarly, in the JUPITER trial, patients were risk
stratified according to elevated high-sensitive c-reactive pro-
tein, enabling the identification of a high-risk population who
then received a more marked benefit from rosuvastatin (hazard
ratio, 0.56 (95% confidence interval, 0.46 to 0.69), P < 0.001)
than has been seen in previous primary prevention trials [41].
The findings from the SCOT-HEART trial are supported
by two other recent studies reviewing patients with stable
angina. The CAPP [42] (cardiac computed tomography for
the Assessment of Pain and Plaque) and CRESCENT [43]
(Computed Tomography vs. Exercise Testing in Suspected
Coronary Artery Disease) trials randomised patients to
CCTA or either exercise electrocardiography or stress echo-
cardiography with approximately 1 year of follow-up. Both
trials showed an increased diagnosis of coronary heart dis-
ease and consequently increased use of preventativemedical
therapies in those allocated to CCTA. In addition, despite
being underpowered for clinical events, both trials demon-
strated lower numerical rates of myocardial infarction
amongst those assigned toCCTA.TheCRESCENT trial also
showed that after CCTA, the final diagnosis was established
sooner (P < 0.0001), and additional downstream testing was
required less frequently compared to functional assessment
(25 vs. 53%, P < 0.0001), resulting in lower cumulative
diagnostic costs [43].
Fig. 3 A 47-year-old man presented with atypical chest pain and was found to have significant non-obstructive proximal right coronary artery disease
and a calcium score of zero
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To add to the above, the Prospective Multicenter Imaging
Study for the Evaluation of Chest Pain (PROMISE) showed that,
although there was no difference in the overall primary outcome,
CCTA predicted subsequent cardiovascular events better than
functional testing [13, 44]. In the CCTAgroup, the majority of
events occurred amongst subjects with non-obstructive coronary
artery disease: disease that would pass undetected by functional
testing and would be less likely to be associated with initiation of
preventative therapy. The investigators also reported that in the
CCTA arm, there was a 34% relative reduction in all-cause death
and myocardial infarction at 12 months in comparison to func-
tional testing (hazard ratio 0.66 (95% confidence intervals, 0.44–
1.00), P = 0.049). Although more patients in the CCTA arm
underwent invasive angiography within the first 90 days, fewer
invasive angiograms without obstructive coronary artery disease
were seen in the CCTA group compared to those who had initial
functional testing.
In addition to these individual studies, a meta-analysis of
randomised controlled trials published in 2016 comparing
CCTA with standard care identified an incidence rate ratio
for myocardial infarction of 0.69 following CCTA (95% CI
0.49–0.98; p = 0.038) [45]: a result entirely consistent with the
SCOT-HEART and PROMISE findings, and confirmed in
two subsequent larger meta-analyses by independent groups
[46, 47]. Finally, reductions in myocardial infarction have also
been reported in a very large (n = 86,705) observational
Danish registry (HR for CCTA: 0.71, 95% CI 0.61 to 0.82)
[48], demonstrating consistency within ‘real world’ practice.
Patients with Acute Chest Pain
There have been several studies assessing the value of CCTA
in the emergency department using a surrogate of early and
safe discharge (Table 3). The largest of them, the American
College of Radiology Imaging Network–Pennsylvania trial
(ACRIN-PA) [49], randomised 1370 low- to intermediate-
risk patients presenting to five emergency departments with
symptoms suggestive of acute coronary syndrome to either
CCTA or traditional chest-pain care. The trial found that
CCTA allowed more patients to be discharged safely than
standard of care (49.6% vs 22.7%), and this led to a shorter
average hospital stay (18 h versus 25 h, p < 0.001). Coronary
artery disease detection rate was also higher in the CCTA
group (9% vs 3.5%) allowing for greater initiation of second-
ary preventative treatment. Similar results were observed in
the ROMICAT-II trial [50] which included 1000 patients aged
40 to 74 years with symptoms suggestive of acute coronary
syndromes, no history of cardiovascular disease and initial
testing (electrocardiogram and troponin measurements) did
not clearly indicate a myocardial infarction. Mean length of
hospital stay was reduced by 7.6 h (P < 0.001) after early
CCTA, as compared with standard of care. Additionally, more
patients assigned CCTA were discharged directly from the
emergency department (47% vs. 12%; P < 0.001). In the
Cardiac-CT in the Treatment of Acute Chest Pain (CATCH)
trial, a CCTA-guided diagnostic strategy improved the posi-
tive predictive value for the detection of coronary stenoses and
increased the frequency of coronary revascularisation when
compared to a conventional functional approach [51].
Similarly, Goldstein et al. in Coronary Computed
Tomographic Angiography for Systematic Triage of Acute
Chest Pain Patients to Treatment (CT-STAT) study showed
that the use of coronary computed tomography angiography
results in more rapid and cost-efficient safe diagnosis than
rest-stress myocardial perfusion imaging in patients with acute
low-risk chest pain [52].
Table 2 Coronary computed tomography angiography in stable chest pain (*FACTOR-64 is a primary prevention study)
Trial Intervention arm Comparator arm Primary end point(s) Follow-up,
month
Min et al., 2012 Coronary computed tomography
angiography (n = 91)
Myocardial perfusion














Composite of death, myocardial
infarction, hospitalisation for
unstable angina, or major
procedural complication
25
SCOT-HEART, 2015 Coronary computed tomography
angiography and standard
of care (n = 2073)
Standard of care
(n = 2073)
Certainty of angina due to
coronary
heart disease at 6 weeks
20
CAPP, 2015 Coronary computed tomography
angiography (n = 243)
ETT,100% (n = 243) Change in angina score from
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A meta-analysis by Gongora et al. [53] showed that CCTA
improves efficiency measures in the acute care settings. It
failed to show reduction in major adverse cardiac events in
patients presenting to the emergency room or admitted for
acute chest pain evaluation but the overall adverse cardiac
event rates were very low since the studies recruited low-
risk and low-to-intermediate risk patients. In this regard, it will
be interesting to see the results of the RAPIC-CTCA trial [54]
which will provide more valuable information regarding the
reduction of MI or cardiovascular death with coronary com-
puted tomography angiography in the acute setting as it will
recruit 2000 higher-risk participants across 35 hospitals in the
United Kingdom. It is the first study to investigate the role of
CCTA in the early assessment of patients with suspected or
confirmed acute coronary syndrome who are at intermediate
risk, including patients with elevated troponin concentrations
or ischaemic changes on the electrocardiogram. All previous
trials in the emergency department have enrolled patients who
are at low risk of acute coronary syndrome, supported by the
exceptionally low subsequent 30-day and 1-year reported
outcomes.
Conclusions
Recent studies as well as large meta-analyses have demon-
strated that the use of CCTA is associated with important
reductions in coronary heart disease death or non-fatal myo-
cardial infarction [55]. It also provides precise disease charac-
terisation and reduces the rate of normal invasive coronary
angiography. The more universal message from these trials
is that the information provided by a diagnostic test can rever-
berate therapeutically beyond making a correct diagnosis of
coronary artery disease and that clinicians should pursue pre-
ventive measures to achieve the best outcomes possible.
Ultimately, the improved diagnosis and treatment of coronary
heart disease coupled together with the treatment of concealed
non-obstructive coronary artery disease underlie and explain
the important beneficial effects of CCTA.
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